The n i f U and n i f S genes encode the components of a cellular machinery dedicated to the assembly of [2Fe-2S] and [4Fe-4S] clusters required for growth under nitrogenfixing conditions. The NifU and NifS proteins are involved in the production of active forms of the nitrogenase component proteins, NifH and NifDK. While NifH contains a [4Fe-4S] cluster, the NifDK component carries two complex metalloclusters, the iron-molybdenum cofactor (FeMo-co) and the [8Fe-7S] P-cluster. FeMo-co, located at the active site of NifDK, is composed of 7 Fe, 9 S, 1 Mo, 1 unidentified light atom, and homocitrate. To investigate whether NifUS are required for FeMo-co biosynthesis and to understand at what level(s) they might participate in this process, we analyzed the effect of nifU and nifS mutations on the formation of active NifB protein and on the accumulation of NifB-co, an isolatable intermediate of the FeMo-co biosynthetic pathway synthesized by the product of the nifB gene. The nifU and nifS genes were required to accumulate NifB-co in a n i f N mutant background. This result clearly demonstrates the participation of NifUS in NifB-co synthesis and suggests an specific role of NifUS as the major provider of [Fe-S] clusters that serve as metabolic substrates for the biosynthesis of FeMo-co. Surprisingly, while nifB expression was attenuated in nifUS mutants, the assembly of the [Fe-S] clusters of NifB was compensated by other non-nif machinery for the assembly of [Fe-S] clusters, indicating that NifUS are not essential to synthesize active NifB.
fixation. The heterotetrameric NifDK protein component (α 2 β 2 dinitrogenase) contains the ironmolybdenum cofactor (FeMo-co) within the active site in the α-subunit (NifD) and has the [8Fe-7S] P-cluster at the interface of the α-and β-subunits (1). The homodimeric NifH (dinitrogenase reductase) contains a [4Fe-4S] cubane and a site for Mg-ATP binding and hydrolysis (2) . These Fe-S clusters of nitrogenase play a critical function in electron transfer and in the reduction of substrates driven by the free energy liberated from Mg-ATP hydrolysis (3) . The [4Fe-4S] cluster carried by NifH is relatively ubiquitous in nature, but the Pcluster and FeMo-co are unique and regarded as some of the most complex metalloclusters known in biology. FeMo-co is composed of 7 Fe, 9 S, 1 Mo, 1 homocitrate, and 1 unidentified light atom (4) (5) (6) .
A systematic genetic and biochemical analysis, mostly in Azotobacter vinelandii and Klebsiella pneumoniae, has revealed complex and specialized cellular biosynthetic pathways for the maturation of the nitrogenase component proteins (see (7) (8) (9) ) for reviews). The products of the nitrogen fixation (nif) genes nifU and nifS are required to achieve full activity of both nitrogenase component proteins. A. vinelandii nifU or nifS deletion mutants exhibited a 15-fold reduction in NifH activity and a 4-fold reduction in NifDK activity (10) . Similar to A. vinelandii, n i f S mutants of K. pneumoniae exhibited negligible NifH activity and a 25-fold reduction in NifDK activity (11) . Since both nitrogenase components are [Fe-S] proteins, it was promptly suggested that NifU and NifS were involved in the formation of [Fe-S] clusters for NifH and NifDK (10) . Later on, in vivo and in vitro experiments demonstrated that NifU and NifS were involved in the assembly of the [4Fe-4S] cluster of NifH (12) (13) (14) .
A series of studies by Dean, Johnson, and coworkers showed that NifU and NifS work in concert to synthesize [Fe-S] clusters under nitrogen fixing conditions and that their roles represent a specialization of the roles performed by the homologous proteins IscU and IscS in general [Fe-S] cluster assembly ((12) and reviewed in (15) ). Each [Fe-S] cluster assembly machinery minimally consists of a sulfurproviding cysteine desulfurase and a molecular scaffold where [2Fe-2S] or [4Fe-4S] clusters are transiently assembled prior transfer to target apoproteins. NifS is a pyridoxal phosphate (PLP)-containing enzyme that catalyzes the desulfurization of L-cysteine to provide sulfur for [Fe-S] cluster formation (16, 17) , and NifU serves as the molecular scaffold for the NifS-directed assembly of [Fe-S] clusters (18, 19) . Indeed, in vitro experiments showed that NifU could transfer a [4Fe-4S] cluster to apo-NifH † and reconstitute an active holo-NifH (14) .
The involvement of NifU and NifS in the assembly of the P-cluster and the FeMo-co embedded within the NifDK protein is less clear. Strains lacking both nifU and nifS exhibited a 10-fold decrease in NifDK activity that could not be recovered by addition of FeMo-co (10) . Complementation by FeMo-co addition is a characteristic property of apo-NifDK containing the P-clusters but lacking FeMo-co. The phenotype of nifUS mutants thus suggests that the absence of NifUS mostly impairs P-cluster synthesis, but does not clarify whether nifUS mutants are capable of synthesizing FeMo-co.
Other nif genes, nifB, nifE, nifH, nifN, nifQ, nifV, and nifX have been shown to be involved in the biosynthesis of FeMo-co (7, 8) . The nifB gene encodes a SAM-radical protein required to synthesize NifB-co, an [Fe-S] cluster of unknown structure that serves as a biosynthetic intermediate during the early steps of FeMo-co biosynthesis (20) (21) (22) . Unlike the wild-type strain, nifN or nifE mutant strains accumulate a measurable amount of NifB-co under nitrogen-fixing growing conditions because the FeMo-co biosynthetic pathway is interrupted at the level of NifB-co processing. NifB-co can be isolated from cytoplasmic membranes of a K. pneumoniae nifN mutant strain by treatment with the detergent sarkosyl (20) .
Radiolabelling experiments with 55
Fe and 35 S isotopes have shown that Fe and S from NifB-co are transferred to FeMo-co during cofactor synthesis in vitro (21) . However, it is not known whether NifB-co is the only source of Fe and S to FeMo-co. NifB-co contains neither Mo nor an organic acid, such as homocitrate (20) .
A standing hypothesis has been that the simple [2Fe-2S] or [4Fe-4S] clusters assembled by NifU and NifS could serve as metabolic substrates during the early steps of FeMo-co synthesis (i. e. the synthesis of NifB-co) (7) (8) (9) . However, direct experimental evidence supporting this hypothesis is lacking. The impairment of nifU and nifS mutant strains to synthesize active NifDK protein could be the result of cumulative effect over the activity of some of the [Fe-S] cluster-containing proteins that are involved in FeMo-co synthesis and NifDK maturation, for example NifH, NifB or NifEN. To address this question, we have investigated here the effect of n i f U and nifS mutations on the accumulation of NifB-co and on the activity of the NifB protein.
EXPERIMENTAL PROCEDURES
K. pneumoniae strains and growth conditions-K. pneumoniae strains UN (wildtype) and UN1217 (nifN4536::mu) has been previously described (23) . Strains generated during the course of this study are described in Supplemental Table S1 . Growth in minimal medium, nif derepression, cell collection, and cell breakage has been described (20) . For growth on plates, LC medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl) was solidified with separately autoclaved 1.5% agar solution. Kanamycin (50 µg/ml), spectinomycin (100 µg/ml), chloramphenicol (17.5 µg/ml), and ampicillin (25 µg/ml) were added as required. A. vinelandii strain UW45 (nifB mutant) (24) was cultivated in 20-l carboys and derepressed for nitrogenase expression as described before (25) . Escherichia coli DH5α, BL21, and S17-1 strains were grown in Luria-Bertani medium at 37˚C with shaking (200 rpm). For growth of E. coli on plates, medium solidified with 1.5% agar was used. Antibiotics were used at standard concentrations (26) .
Plasmid constructions and DNA manipulations-Plasmid constructions, PCR, and transformation of E. coli were carried out by standard methods (26) . Plasmids generated during the course of this work are listed in Supplemental  Table S1 . Isolation of genomic DNA from K. pneumoniae strains was carried out using the DNAeasy TM Tissue Kit (Qiagen). Procedures for K. pneumoniae transformation (27) , conjugation and gene replacement (28) have been described.
Generation of K. pneumoniae nifU and nifS mutant strains-Mutations in nifU or n i f S consisted of in-frame deletions spanning the complete amino acid coding sequences of nifU or nifS without altering any other DNA sequence in the nif gene cluster (Fig. 1) . These deletions were constructed on suicide plasmids to force recombination with the genomic DNA of K . pneumoniae UN1217 and to promote exchange of gene alleles. Oligonucleotides were designed to amplify by PCR the nif DNA regions flanking nifU or nifS using K. pneumoniae genomic DNA as template. DNA fragments were amplified using Pfu DNA polymerase and ligated into the corresponding restriction sites of plasmid pEP185.2 to construct pRHB288 (Δ nifU) , pRHB289 (Δ nifS), and pRHB290 (Δ nifUS), respectively. In pRHB288 (ΔnifU), the 1.9-kb KpnI DNA fragment containing part of nifN and the complete nifX was blunt-end ligated to the 2.5-kb PstI DNA fragment containing the nifSVW genes. In pRHB289 (ΔnifS), the 2.73-kb KpnI DNA fragment containing part of nifN and the complete nifX and nifU genes was blunt-end ligated to the 1.26-kb P s tI DNA fragment containing the complete n i f V W genes. In pRHB290 (ΔnifUS), the 1.9-kb KpnI DNA fragment containing part of nifN and the complete nifX gene was blunt-end ligated to the 1.8-kb NotI DNA fragment containing the complete nifVWZ genes. Plasmid pRHB291 was generated from pRHB290 by replacing the 630-bp DNA fragment between two BamHI restriction sites within nifX and n i f V by the 1.2-kb kanamycin resistance cassette from pUC4K. Fidelity of all constructions was confirmed by sequencing both DNA strands.
The nifU and nifS mutations were introduced into the chromosome of strain UN1217 by allelic exchange events. First, UC0 was generated by conjugation of K. pneumoniae UN1217 with E . coli S17-1 (pRHB291) followed by selection of a Km r Cm s phenotype. After isolating genomic DNA from resulting Km r Cm s colonies, incorporation and segregation of mutant allele into the chromosome was checked by PCR. Second, pRHB288 (Δ nifU), pRHB289 (Δ n i f S ), or pRHB290 (ΔnifUS) were transferred to strain UC0 by conjugation to generate UC1, UC2, and UC3, respectively. Amp r Cm r clones with plasmids integrated into the chromosome by single crossover events were selected and confirmed by PCR analysis. Third, selected Amp r Cm r clones were continuously cultured in liquid LC medium containing 25µg/ml ampicillin for more than 100 generations to enrich for cells having the second allelic exchange. Cultures were then diluted and plated onto solid LC medium containing 25 µg/ml ampicillin, or 25 µg/ml ampicillin plus 50 µg/ml kanamycin. Km s Cm s colonies (which had a second allelic exchange event) were selected and the deletions in nifU, nifS, or nifU and nifS were confirmed by PCR analysis (Fig. 1) .
Genetic complementation of ΔnifU, ΔnifS, and Δ nifUS mutant strains-To perform genetic complementation analysis of ΔnifU and Δ nifS mutants, strains UC1, UC2 and UC3 were transformed with plasmid pRHB257 according to (27) . Plasmid pRHB257 is a derivative of the low copy number plasmid pEXT21 that carries wildtype n i f U S genes. Plasmid pRHB257 was generated by cloning a 2275-bp BamHI DNA fragment, which covers from the restriction enzyme site at the 3' end of nifX to the stop codon of nifS, into the B a m HI and HindIII sites of pEXT21 (Fig. 1) .
Generation and expression of GST-NifB fusion proteins in K. pneumoniae-NifB from K. pneumoniae was expressed as a glutathione-Stransferase (GST) fusion protein. The chimera was constructed in the pRHB153 plasmid, a derivative of plasmid pGEX-4T-3 (GE Healthcare) (29) . The nifB gene was PCR-amplified from the chromosome of K. pneumoniae UN1217 using o l i g o n u c l e o t i d e s n i f B -N 1 5 ' -CCCCATATGACTTCCTGCTCCTCTTTTTCTG G -3 ' a n d n i f B -C 1 5 ' -GGGCTCGAGTCAGGCGACCCCCTTATGCG-3' as primers. The nifB gene cartridge was then digested with NdeI and BamHI and ligated into the corresponding sites of plasmid pRHB153 to generate plasmid pRHB233.
Two strategies were used to express gst-nifB at different cellular levels. First, to keep gst-nifB expression at wild-type levels, the chromosomal copy of nifB was replaced by a gst-nifB allele so that expression was controlled by the natural nifB promoter. A 1-kb DNA fragment containing the nifA gene, the nifB promoter (PnifB), and a XbaI restriction site at the 5' end, was PCR-amplified from the chromosome of K. pneumoniae UN1217 using oligonucleotides n i f A -m 1 5 ' -CCCCTCTAGAATCGCCAACGCCATCCACCA T A A T -3 ' a n d n i f A -c 1 5'-GGTCGTACCTTCGTGGTTGGGC-3' as primers. In addition, a 2.1-kb DNA fragment containing the gst-nifB gene and a SacI restriction site at the 3'end was PCR-amplified from pRHB233 using oligonucleotides RNF17 5'-ATGTCCCCTATACTAGGTTATTGGAAATTA A G -3 ' a n d n i f B -c 3 5 ' -CCGAGCTCTCAGGCGACCCCCTTATGCGGC AA-3' as primers. Both DNA fragments were ligated into the XbaI and SacI sites of the suicide plasmid pDS132, which carries a sacB gene (30) , to generate plasmid pRHB292. Plasmid pRHB292 was transferred to strains UN (wild-type), UN1217 (nifN::mu), and UC3 (Δ nifUS nifN::mu) to generate strains UC4, UC5, and UC8, respectively. After selecting Cm r clones, the integration of pRHB292 into the chromosome was confirmed by PCR analysis. Clones with integrated pRHB292 were cultured in liquid LC medium and subsequently plated onto solid LB medium supplemented with 5% sucrose to select for plasmid excision in sucrose-resistant colonies. Substitution of gst-nifB for nifB was confirmed by PCR analysis of chromosomal DNA isolated from strains UC4, UC5 and UC8. Cells from K. pneumoniae UC5 and UC8 strains were grown, derepressed for nitrogenase, and collected by standard procedures (20) .
The second strategy aimed at boosting expression of gst-nifB up to levels that facilitated purification of NifB. To achieve this, the wild-type copy of nifB was removed from the chromosome of UN1217 and the gst-nifB gene was expressed from plasmid pRHB233 so that expression was controlled by an IPTG-inducible Ptac promoter. A 1-kb XbaI-EcoRI DNA fragment containing nifA, and a 1-kb EcoRI-SphI DNA fragment containing nifQ, were amplified from UN1217 genomic DNA by PCR and ligated into the XbaI and SphI sites of pDS132 to generate plasmid pRHB235 (ΔnifB). Plasmid pRHB235 was transferred to strains UN (wild-type), UN1217 (nifN::mu), and UC3 (ΔnifUS nifN::mu) to generate strains UC9, UC10, and UC11, respectively, by a procedure analogous to that described above for gst-nifB replacement. Finally, plasmid pRHB233 was transferred to UC9, UC10, and UC11 mutant strains for GSTNifB expression under different genetic background generating strains UC16, UC17, and UC18, respectively. Cells from K. pneumoniae UC16, UC17 and UC18 strains were subjected to ITPG induction (5 µM IPTG) and nif-derepression at the same time.
Generation of a K. pneumoniae nifENX mutant strain-A K. pneumoniae ΔnifENX mutant strain (UC15) was generated. A nifTY-nifU DNA fragment having a complete deletion of the nifENX operon deleted was first cloned in plasmid pDS132 and then introduced into the chromosome of K. pneumoniae UN by allelic exchange to generate UC15. A 986-bp nifTY DNA fragment carrying XbaI restriction site at the 5' end and EcoRI restriction site at the 3' end was amplified by PCR using
. A 1053-bp nifU DNA fragment carrying EcoRI restriction site at the 5' end and an SphI restriction site at the 3' end was amplified by P C R u s i n g p r i m e r s n i f U -
). Both DNA fragments were digested by the corresponding restriction enzymes and coligated into the XbaI and SphI sites of pDS132 to generate plasmid pRHB294. Transfer of pRHB294 into K. pneumoniae UN, clone selection, and segregation of ΔnifENX mutation was performed using plasmid pDS132 as described above. Deletion of nifENX genes from the chromosome of UC15 was confirmed by PCR analysis. Strain UC15 did not exhibit nitrogenase activity in vivo, as expected.
Purification of GST-NifB from K. pneumoniae cells-GST-NifB proteins were purified from cells of strains UC5, UC8, UC17, and UC18 by affinity chromatography using GSH-Sepharose resin (GE Healthcare). For preparation of GSTNifB, twenty-five g of collected cell paste were resuspended in 80 ml of 2x buffer A (10 mM sodium phosphate, 1.8 mM potassium phosphate buffer, pH 8.5, 140 mM NaCl, 2.7 mM KCl, 10% glycerol, 5 mM β-mercaptoethanol, 0.02% DDM, 0.2 mM PMSF, 0.5 µg/ml leupeptin, 5 µg/ml DNaseI, and 1 mM DTH). Cells were disrupted by 10 cycles of sonication (1 min per cycle) using a Fisher Sonic Dismembrator 550 equipped with 12 mm tip at 25% power output inside an anaerobic glove box. After adjusting pH of lysate to pH 7.4, cell debris was removed by centrifugation at 27,000 x g for 30 min in a Beckman Ti 50.2 ultracentrifuge rotor. The clarified cell-free extract (supernatant) was applied onto a 5-ml GSHSepharose column. The column was then washed with three column volumes of buffer A supplemented with 1% Triton X-100 and 10 column volumes of buffer A to remove contaminants. The GST-NifB was eluted from the column applying three column volumes of buffer B (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 0.02% DDM, 0.2 mM phenylmethylsulfonyl fluoride, 0.5 µg/ml leupeptin, 10 mM reduced glutathione, and 1 mM DTH). Eluted GST-NifB protein was concentrated to 3-5 mg/ml inside an anaerobic glove box using an Amicon cell equipped with YM100 Millipore ultrafiltration membranes. Purification of the GSTNifB fusion protein was accomplished within six hours at 16°C. Purified NifB preparations were drop-frozen and stored in liquid nitrogen.
In vivo and in vitro nitrogenase activities-In vivo nitrogenase activity was determined by ethylene production at 30 °C for 30 min in 1-ml culture samples as previously described (31) . NifDK activity in cell-free extracts was obtained after titration with an excess of the complementary component, NifH, as described (32) . Specific activity is defined as nmol of ethylene formed per min/mg of protein in the extract. (33) , NifB-co (20) have been described. Preparation of crude NifB-co extracts was carried out according to (20) with a modified cell breakage procedure. K. pneumoniae cells in a 3 ml suspension were broken inside an anaerobic glove box by sonication for 2 minutes and 15% power output using a Fisher Sonic Dismembrator 550 equipped with a 3 mm tip. Crude NifB-co extract refers to NifB-co solubilized from lysed cells of K. pneumoniae strains with Sarkosyl detergent (nlauroyl sarcosine) but not purified through further chromatographic steps.
In vitro FeMo-co-dependent or NifB-cod e p e n d e n t a p o -N i f D K a c t i v a t i o n assays-Protocols for the isolation of FeMo-co
Assays for NifB-co dependent in vitro activation of apo-NifDK present in extracts of A. vinelandii strain UW45 (nifB) were performed as described in (20) with modifications. Nine-ml serum vials sealed with stoppers were repeatedly evacuated and flushed with argon gas and rinsed with 0.3 ml of anaerobic buffer. The complete reactions contained: 100 µl of 25 mM Tris-HCl buffer pH 7.5, 10 µl of 1 mM Na 2 MoO 4 , 20 µl of 5 mM homocitrate, 200 µl of ATP-regenerating mixture (containing 3.6 mM ATP, 6.3 mM MgCl 2 , 51 mM phosphocreatine, 20 units/ml creatine phosphokinase, and 6.3 mM DTH), 200 µl of UW45 cell-free extracts (≈3 mg of protein), and 50 µl of crude NifB-co extract from the K . pneumoniae strain being analyzed. The reactions were incubated at 30°C for 35 min to allow for the FeMo-co synthesis and insertion reactions. The resulting activation of apo-NifDK present in UW45 extract was analyzed by the acetylene reduction assay after adding 0.8 ml of ATPregenerating mixture and an excess of purified NifH (0.2 mg of protein) (32) .
FeMo-co precursor activity present in purified GST-NifB preparations was analyzed in the UW45 crude extract-based assay as described above except that purified GST-NifB substituted for NifB-co in the reaction mixture.
FeMo-co insertion assays into apo-NifDK were performed as described in (34) .
Apo-NifDK activation assay with purified components-FeMo-co synthesis and apo-NifDK § activation assays with purified components were set in 406 µ l reaction mixtures inside 9 ml anaerobic vials. Apo-NifDK reconstitution was dependent on the NifB-co activity associated with purified NifB protein and therefore no extra source of Fe, S or SAM was added to the assay. Twohundred µl of ATP-regenerating mixture, 100 µl of 25 mM Tris-HCl pH 7.4, 20 µ l of 5 mM homocitrate, and 10 µl of 1 mM Na 2 MoO 4 were mixed and incubated at room temperature for 10 min. Reactions were then initiated by adding the purified protein components, namely precursorfree NifEN, NifH, apo-NifDK, and GST-NifB to final concentrations of 1.1 µM, 14.3 µM, 1.1 µM, and 4.5 µM, respectively. Precursor-free NifEN was purified from A. vinelandii strain UW243 (29), NifH was purified from A. vinelandii strain DJ884, and apo-NifDK was purified from A . vinelandii strain DJ1143 (35) (32) .
SDS-PAGE, anoxic native-gel electrophoresis, and immunoblot analysis-The procedure for SDS-PAGE has been described (36) . Immunoblot analysis was performed as described by Brandner et al. (37) . Purified preparations of K. pneumoniae NifB were used to raise anti-NifB antibodies at Capralogics Inc, (Hardwick, MA). For anoxic native-gel electrophoresis, proteins were separated on gels with superimposed 7-20% acrylamide and 0-20% sucrose gradients as described (29) . Native gels were then stained for proteins with Coomassie R-250 by standard procedures, or stained for iron as described in (38) .
UV-Visible spectroscopy-The UV-visible spectra were determined using a Shimadzu UV-1601 spectrophotometer.
Miscellaneous assays-Protein concentrations were determined by the bicinchoninic acid method using BSA as standard (39) . Fe content in purified GST-NifB preparations was determined according to (40).
RESULTS

K. pneumoniae nifU and nifS mutants fail to
accumulate NifB-co-Strain UN1217 carries a mutation in nifN that impairs FeMo-co synthesis and results in the accumulation of NifB-co activity (20) . NifB-co activity levels in K. pneumoniae strains that combine mutations in n i f N with deletions of nifU, nifS, or both nifU and nifS were determined and are presented in Table 1 . NifB-co activity levels in extracts of K. pneumoniae strains were determined by using the NifB-co-dependent FeMo-co synthesis and apo-NifDK activation assay (20) . This assay is based on the biochemical complementation of a cell-free extract from a ΔnifB A. vinelandii strain (UW45) with a sample containing NifB-co activity. In this assay, FeMoco is synthesized in vitro and inserted into apoNifDK present in the UW45 extract to reconstitute nitrogenase activity. Crude NifB-co preparations from cell-free extracts of strains UC1 (ΔnifU nifN::mu), UC2 (Δ nifS nifN::mu), and UC3 (ΔnifUS n i f N::mu) were unable to reconstitute NifDK activity, indicating that they did not accumulate enough NifB-co to support NifB-codependent FeMo-co synthesis (Table 1) .
Genetic complementation experiments confirmed that the lack of NifB-co activity in extracts of strains UC1, UC2, and UC3 was specifically due to mutations in nifU and nifS genes. The nifU and nifS genes were cloned into the low-copy plasmid pEXT21 under the control of the n i f U promoter to generate plasmid pRHB257, which in turn was used to transform strains UC1, UC2, and UC3 (Fig. 1) . Table 1 shows that NifB-co preparations from extracts of strains UC1, UC2 and UC3, carrying pRHB257, have the ability of support NifB-co-dependent apo-NifDK activation to levels similar to those observed in strain UN1217, indicating that the expression of nifU and nifS from pRHB257 restores the intracellular accumulation of NifB-co.
These results demonstrate that NifU and NifS were required for the accumulation of NifB-co in a nifN mutant background.
NifB overexpression partially overcomes the effect of nifUS deletion on NifB-co accumulation-Two strategies were used to express NifB at different levels and examine the relationship between NifB protein levels and NifB-co activity (Fig. 2) . The first was to substitute gst-nifB for nifB in the chromosome of K. pneumoniae while keeping wild-type expression levels (strains UC4, UC5 and UC8). This strategy allowed examination of GST-NifB and NifB-co levels under normal nif regulatory conditions. The second was to delete nifB from the chromosome and introduce a plasmid carrying a gst-nifB gene under an IPTG-inducible P t a c promoter (strains UC16, UC17 and UC18). This strategy uncouples nifB expression from nif transcriptional regulation. In addition, NifB expression is enhanced allowing purification and analysis of purified GST-NifB from different genetic backgrounds (see below).
Strains UC4 ( gst-nifB), UC5 (nifN::mu, gstnifB) and UC8 (ΔnifUS nifN::mu, gst-nifB) were generated from the parental strains UN, UN1217 and UC3, respectively (Fig. 2) . Incorporation of the GST tag into NifB did not impair in vivo nitrogenase activity in K. pneumoniae UC4 cells. K. pneumoniae strain UC4, which expresses GSTNifB protein in a wild-type genetic background, exhibited in vivo nitrogenase activity (943 nmol C 2 H 4 formed/hour/OD 600 ) very similar to that of the wild-type UN strain (817 nmol C 2 H 4 formed/hour/OD 600 ). Fig. 2B shows that strain UC8 accumulates 10-fold less GST-NifB than strain UC5, suggesting an effect of ΔnifUS mutation in either expression or stability of GST-NifB. In addition, UC8 cells were severely affected in the accumulation of NifB-co, the metabolic product of NifB activity. While UC5 cells exhibited similar NifB-co activity levels to those of the parental strain UN1217, NifB-co activity extracted from UC8 cells was remarkably low and consistently undistinguishable from the background of the UW45 extracts used in that particular assay (Table  2) .
Several differences were apparent in strain UC17 in which GST-NifB expression was driven by the tac promoter instead of the endogenous nifB promoter. First, GST-expression (Fig. 2B) and NifB-co activity (Table 2 ) increased 10-fold and 2-fold, respectively. The fact that UC17 cells over expressing NifB contain higher levels of NifB-co suggests that the NifB levels present in a wild type strain could be a limiting factor for NifB-co synthesis. Second, the ΔnifUS mutation did not have a major effect in the in vivo levels of GSTNifB protein (compare GST-NifB levels in UC17 versus UC18 to those in UC5 versus UC8), which suggests that the effect of the ΔnifUS mutation on GST-NifB levels observed in UC8 was mainly due to changes in expression rather than in NifB stability. Third, in a ΔnifUS genetic background, UC18 cells over expressing GST-NifB exhibited more NifB-co activity than UC8 cells (Table 2) , uncovering a NifUS-independent pathway that can partially substitute for the function of NifUS when NifB is overexpressed.
The products of nifU and nifS are not required to synthesize a functional NifB protein-
T h e failure of strains UC1, UC2, and UC3 to accumulate NifB-co in a nifN background led to several hypothetical scenarios: (i) it is possible that NifU and NifS directly provide the [Fe-S] cluster substrates for NifB activity to transform into NifB-co, (ii) it is possible that NifU and NifS are involved in the synthesis of a functional NifB protein, which itself is an [Fe-S] protein or, (iii) a combination of both scenarios. To discriminate between these possibilities, we compared the iron content, UV-visible absorption spectrum, and specific activity of NifB protein purified from a nifN mutant strain to those of NifB purified from a mutant strain lacking nifN and nifUS.
GST-NifB proteins were purified from cells of strains UC17 (ΔnifB nifN::mu, Ptac-gst-nifB) and UC18 (ΔnifB ΔnifUS nifN::mu, Ptac-gst-nifB) that had been derepressed for nitrogenase activity as described in Experimental Procedures (Fig. 3A) . A typical purification procedure yielded 15 mg of GST-NifB protein from 45 g of K. pneumoniae cells. The NifB purification yields from UC17 and UC18 cells were similar, what was consistent with the similar levels of in vivo NifB expression in UC17 and UC18 strains, as determined by immunoblot analysis (Fig. 2B) , Hereafter, we refer to NifB preparations as GST-NifB and ΔnifUS GST-NifB when purified from UC17 or UC18 cells, respectively. Purified preparations of GSTNifB and ΔnifUS GST-NifB contained similar amounts of Fe (10.3 ± 1.1 mol Fe/mol GST-NifB monomer compared to 8.7 ± 0.1 mol Fe/mol ΔnifUS GST-NifB monomer) and showed similar UV-visible absorption spectra (Fig. 3B) , suggesting that nifU and nifS were not essential for the synthesis of the [Fe-S] clusters of NifB. As a SAM-radical enzyme, each NifB monomer is expected to contain at least one permanent [4Fe-4S] cluster coordinated by three cysteine residues and a molecule of SAM. Thus, the Fe content of purified GST-NifB preparations would be enough to account for the presence of the permanent [4Fe-4S] cluster and additional [Fe-S] cluster(s).
Purified GST-NifB was active in the in vitro FeMo-co synthesis assay in which GST-NifB substitutes for NifB-co. Titration of a FeMo-co synthesis reaction based on UW45 cell-free extract with purified GST-NifB shows that non-saturating concentrations of ΔnifUS GST-NifB provided 63 ± 4 % precursor activity compared to the GST-NifB protein (Fig. 4) . This result suggests that the load of FeMo-co precursor in purified ΔnifUS GSTNifB was less than in purified GST-NifB and is consistent with the slightly lower Fe content exhibited by ΔnifUS GST-NifB preparations. Both titrations saturated at similar activity levels at which another component of the reaction mixture becomes limiting. The FeMo-co synthesis assay based on UW45 extracts contains 3.2 mM DTH. It has been shown that neither NifS (41) nor NifU (19) are functional in the presence of 2 mM DTH. Thus, it is unlikely that an in vitro activity of NifUS could load GST-NifB with a FeMo-co precursor under the conditions of this assay.
To further rule out in vitro complementation of NifU and NifS present in an UW45 extract and confirm that purified GST-NifB proteins carried FeMo-co precursors, GST-NifB and ΔnifUS GSTNifB were assayed for in vitro FeMo-co synthesis in a reaction with purified components (Table 3) . Both forms of GST-NifB proteins produced similar apo-NifDK activation levels in the assay with purified components. Unlike what has been reported for A. vinelandii purified NifB protein (22) , the GST-NifB protein, as purified from K. pneumoniae cells, did not require addition of Fe, S, and SAM for in vitro activity. Thus, GST-NifB appeared to be loaded with FeMo-co precursor activity (presumably NifB-co). In fact, addition of 0.42 mM (NH 4 ) 2 Fe(SO 4 ) 2 , 0.42 mM Na 2 S, and 0.88 mM SAM to these reaction mixtures resulted in a slight decrease in the level of reconstituted NifDK activity (data not shown).
Accumulation of FeMo-co precursor on K. p n e u m o n i a e NifB was not caused by the interruption of FeMo-co synthesis pathway in a nifN::mu strain because GST-NifB purified from a wild-type genetic background (strain UC16) also carried FeMo-co precursor activity ( Table 3) .
The above results can be summarized as follows: (i) NifU and NifS are not required for the synthesis of a functional SAM-radical NifB protein, (ii) GST-NifB preparations purified from a ΔnifUS strain carry substantial amounts of FeMo-co precursor (presumably NifB-co), and (iii) n i f U and nifS mutants do not synthesize enough NifB-co as to observe its accumulation in a strain (nifN::mu) unable to process it into FeMoco. These results strongly support the hypothesis in which NifU and NifS are the main providers of [Fe-S] cluster substrates that are converted into NifB-co by the activity of NifB. They also indicate that in the absence of NifU and NifS, another cellular [Fe-S] cluster assembly machinery is able to support low levels of NifB-co synthesis.
R o l e o f N i f X i n N i f B -c o accumulation-Although the NifB protein copurifies with a small fraction of NifB-co activity present in cellular extracts of K. pneumoniae UN1217 (nifN::mu), most of the NifB-co activity pool accumulates elsewhere in the cell, probably in a protein-bound form. The main candidate would be NifX, which is known to be a NifB-co binding protein (42). The transfer of NifB-co from NifB to NifX was tested in vitro and the results are shown in Fig. 5 . Incubation of purified GST-NifB with NifX followed by separation of both proteins by anoxic native gel electrophoresis results in the transfer of an entity containing Fe from NifB to NifX (Fig. 5, lanes 1-2) . This Fe-containing moiety presumably represents NifB-co because a NifX/NifB-co complex generated in vitro by incubating together purified samples NifX and NifB-co migrates to the same position in the gel (Fig. 5, lane 6) . Importantly, NifX has been shown not to bind free Fe (29) . Purified ΔnifUS GSTNifB was also able to transfer Fe to NifX (Fig. 5,  lanes 3-4) , consistent with the presence of NifB-co activity in ΔnifUS GST-NifB preparations. This result shows that NifB-co can be transferred from NifB to NifX in vitro and suggest this could also be the case in vivo.
To test whether the pool of NifB-co activity accumulated in nif-derepressed UN1217 cells was dependent on the presence of NifX, we analyzed the accumulation of NifB-co activity in a K . pneumoniae ΔnifENX mutant strain (UC15). Table  4 shows that strain UC15 exhibited similar levels of NifB-co activity than strain UN1217, indicating that NifX was not essential for NifB-co accumulation in vivo. In addition, the phenotype of UC15 completely rules out the possibility that NifB-co activity could be associated to the remaining NifE polypeptide of UN1217 (nifN::mu). Thus, the majority of the NifB-co pool in strain UC15 and, probably, in UN1217 might be bound to an unidentified carrier other than the NifB, NifX, or NifEN proteins.
DISCUSSION
Dean and co-workers first suggested that NifU and NifS were involved in the maturation or stability of both nitrogenase component proteins because A. vinelandii nifU or nifS deletion mutants exhibited a 15-fold reduction in NifH activity and a 4-fold reduction in NifDK activity (10) . Similar to A. vinelandii, nifS mutants of K. pneumoniae exhibited negligible NifH activity and a 25-fold reduction in NifDK activity (11) . In vivo and in vitro evidence have conclusively supported a specific role of NifU and NifS in the assembly and incorporation of the [4Fe-4S] cluster into NifH (12) (13) (14) .
The exact roles of NifU and NifS in the assembly of the complex [Fe-S] clusters of NifDK are less conclusive. Although their involvement in the assembly of a functional NifDK protein has been established from genetic experiments, finding the specific step(s) at which NifUS participate in this process has been particularly difficult. Many of the proteins that participate in FeMo-co biosynthesis, such as NifB, NifEN and NifH, are [Fe-S] proteins and an impairement in FeMo-co synthesis could initially be attributed to a defect in any of those proteins. The only protein conclusively shown to be involved in the biosyntheses of the P-cluster and FeMo-co is NifH. Two lines of evidence are inconsistent with the possibility that the effect of nifUS mutations on FeMo-co biosynthesis could be mediated by the inability to assemble the [4Fe-4S] cluster of NifH. First, it was shown that a [4Fe-4S] clusterdeficient form of NifH (apo-NifH) was fully competent for FeMo-co synthesis and apo-NifDK maturation in vitro (43). Second, deletion of the rnf gene clusters of A. vinelandii, which results in deficient incorporation of Fe into NifH and a 100-fold decrease in NifH activity, had no effect on the levels of NifDK activity (44) .
To investigate whether [Fe-S] clusters assembled by NifU and NifS could serve as substrates for FeMo-co synthesis, we took advantage of the fact that a K. pneumoniae nifN::mu strain (UN1217) accumulates substantial amount of an isolatable FeMo-co precursor that is synthesized by the activity of NifB (NifB-co). Analyzing the effect of nifU and nifS mutations on the accumulation of NifB-co and on the activity of the NifB protein was necessary to clarify the participation of NifU and NifS in the early steps of FeMo-co biosynthesis, because it excludes the effects mediated by the activities of other [Fe-S] proteins involved in the pathway (e.g. NifEN, NifH, and apo-NifDK).
Two domains have been identified in NifB. The N-terminal domain has similarity to SAMradical proteins and was proposed to contain a [4Fe-4S] center coordinated by three cysteine residues and a molecule of SAM (22) . The Cterminal domain is similar to NifX, and is shared by a family of proteins that show FeMo-co precursor binding activity (34) . NifB proteins purified from K. pneumoniae cells exhibit similar Fe contents and UV-visible spectra regardless of the presence or absence of nifUS. Thus, the function of NifUS in the assembly of (at least) some of the Other functions of NifUS appeared not to be compensated by the additional [Fe-S] cluster assembly machineries, because a K. pneumoniae ΔnifUS n i f N : : m u mutant strain does not accumulate NifB-co. The 10-fold decrease in NifB polypeptides exhibited by this mutant would contribute to its failure to accumulate NifB-co. A general attenuation of accumulation of nif gene products in K. pneumoniae nifUS mutants has been previously observed (11) . The mechanism underlying nifUS requirement for maximal expression of nif genes is not understood. To circumvent this effect, nifB expression was uncoupled from Nif regulation of transcription by using an IPTG-inducible P tac promoter. When nifB expression was driven by the P tac promoter, the absence of nifUS had no effect on the levels of NifB polypeptides. However, accumulation of NifB-co activity was still low, suggesting that in vivo NifB-co synthesis was ocurring at lower rates in the absence of nifUS.
The data presented in this study suggest that although a strain lacking n i f U S does not accumulate significant levels of NifB-co, it has the capability to assemble a functional NifB protein.
The GST-NifB proteins purified from wild type or ΔnifUS genetic backgrounds not only exhibited similar Fe contents and UV-vis spectra, but also similar levels of associated NifB-co activity as determined by in vitro FeMo-co synthesis assays. In addition, both the GST-NifB and the ΔnifUS GST-NifB proteins seem to be able to transfer NifB-co to NifX, as suggested by the transfer of Fe label between the two proteins determined by anoxic native-gel electrophoresis. However, the amount of NifB-co activity associated with NifB represents only a small fraction of the cellular NifB-co pool, which size was shown to be NifUSdependent. The main reservoir of NifB-co does not involve the NifB-co binding proteins NifEN or NifX because a K. pneumoniae strain lacking the nifENX genes accumulated similar NifB-co activity than UN1217. Whether NifB-co binds to another unidentified NifB-co binding protein remains uncertain.
Purified preparations of K. pneumoniae GSTNifB supported in vitro FeMo-co synthesis without a requirement for Fe, S, or SAM. This result indicates that, as-isolated, K. pneumoniae NifB carries a FeMo-co precursor (probably NifBco). Unlike the purified preparations of K . pneumoniae GST-NifB, the preparations of "asisolated" A. vinelandii His-NifB protein do not contain NifB-co activity in any of the genetic backgrounds analyzed so far (22, 45) and require addition of Fe, S and SAM to support in vitro FeMo-co synthesis. In addition, GST-NifB purified from K. pneumoniae contains 10 Fe atoms per monomer compared to 6 Fe atoms per monomer present in His-NifB purified from A. vinelandii. These differences between the "asisolated" NifB proteins from K. pneumoniae and A. vinelandii could be caused by the different purification procedures used, or it could actually reflect different properties of both enzymes. Interestingly, when chemically reconstituted, purifed A. vinelandii His-NifB protein incorporates three extra Fe atoms per monomer and becomes active in vitro. Understanding these differences might provide some insights into the mechanism of the reaction catalyzed by NifB.
Taken together, the results of this work clearly demonstrate the participation of NifU and NifS in NifB-co biosynthesis and hence in FeMo-co biosynthesis. Two different interpretations of the phenotype of a Δ nifUS mutant strain and the specific function(s) of NifUS in NifB-co biosynthesis arise from the present study. First, the NifUS system is the major contributor of the overall metabolic flux through NifB by providing [Fe-S] precursors for NifB-co synthesis. The lack of NifUS activities in ΔnifUS mutants can be marginally compensated by the activity of any of the other general machineries for the assembly of simple [Fe-S] clusters present in K. pneumoniae (Fig. 6) . Second, NifU and NifS would not be required to assemble the [Fe-S] clusters that are hypothesized to become NifB-co by the SAM radical-dependent activity of NifB. Rather, NifU and NifS would be required to accumulate NifBco after it has been synthesized by an unknown mechanism that does not involve NifEN or NifX. While the experimental evidence presented herein strongly supports the first interpretation and is in line with previous genetic information (10, 11) , identification and characterization of the putative NifB-co accumulating mechanism would be necessary to support the second interpretation.
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Fish KEY WORDS nitrogenase/nif/FeMo-co/iron-sulfur/molybdenum ABBREVIATIONS FeMo-co, iron-molybdenum cofactor; NifB-co, NifB-cofactor; NifDK, MoFe protein or dinitrogenase; NifH, Fe protein or dinitrogenase reductase; nif, genes encoding proteins involved in nitrogen fixation; DTH, sodium dithionite; DDM, n-dodecyl-β-D-maltopyranoside; PMSF, phenylmethylsulfonyl fluoride; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SAM, S-adenosyl methionine; Sarkosyl, n-lauroyl sarcosine. FOOTNOTES † Apo-NifH refers to a form of NifH which [4Fe-4S] cluster has been removed by chelation. § A form of apo-NifDK that contains the P-clusters but lacks FeMo-co (ΔnifB his-tagged apo-NifDK) was used for these studies (35) . When purified by metal-affinity and ion-exchange chromatography, this form of apo-NifDK does not contain the NafY subunit. FIGURE LEGENDS FIGURE 1. Scheme showing the genetic organization of K. pneumoniae strains UN1217, UC0, UC1, UC2, and UC3 in the chromosomal region around nifU and nifS. Plasmid pRHB257, used for genetic complementation analysis, contains the nifU and nifS genes cloned into pEXT21. FIGURE 2. GST-NifB protein levels in nifN::mu and nifN::mu ΔnifUS genetic backgrounds. A, scheme showing the wild-type chromosomal region around nifB and the genetic constructions to express gst-nifB from the PnifB promoter in the chromosome (strains UC4, UC5 and UC8) or from the Ptac promoter present in plasmid pRHB233 (strains UC16, UC17, and UC18). B, GST-NifB levels in nitrogenase derepressed cells of UC5 (nifN::mu, gst-nifB), UC8 (nifN::mu ΔnifUS, gst-nifB), UC17 (nifN::mu ΔnifB, Ptac-gst-nifB), and UC18 (nifN::mu ΔnifB ΔnifUS, Ptac-gst-nifB). Cells from nifderepressed cultures were collected and boiled in SDS loading buffer. UC17 and UC18 cultures were nifderepressed and IPTG-induced. To help comparing GST-NifB levels between strains, the amount of UC5 and UC8 cells loaded in the gel was seven-fold higher than UC17 and UC18. After SDS-PAGE, proteins in the gel were transferred to nitrocellulose membranes and GST-NifB was detected by immunoblot developed with antibodies to NifB and quantified by densitometry. TABLE 1 Determination of NifB-co activity in K. pneumoniae ΔnifU, ΔnifS, and ΔnifUS mutant strains Details for the complete NifB-co dependent FeMo-co synthesis and apo-NifDK activation assay can be found at the "Experimental Procedures" section. The amount of apo-NifDK from UW45 extracts reconstituted in vitro was determined by measuring acetylene reduction activity of matured NifDK. Activation of apo-NifDK present in UW45 extracts with an excess of isolated FeMo-co gives 13 nmol ethylene formed per min/mg protein in the extract. 
Strain
TABLE 2
NifB-co activity in K. pneumoniae nifN::mu and ΔnifUS nifN::mu strains expressing GST-NifB Crude NifB-co extracts were prepared as described in "Experimental Procedures". Reaction conditions were the same as those in Table 1 . Values are the averages of two to seven assays performed separately. Specific activities are expressed as nmol ethylene formed per min/mg protein in UW45 extract. Activation of apo-NifDK present in UW45 extracts with an excess of isolated NifB-co gives 12.9 ± 1.0 nmol ethylene formed per min/mg protein in the extract. 
